MORRISTOWN, N.J., March 09, 2023 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will be participating in investor meetings at the Barclays Global Healthcare Conference at the Loews Miami Beach Hotel on March 14, 2023.
Meeting Details
For investors attending the conference who wish to meet with the Intercept management team, please reach out to Nareg Sagherian at Intercept to check the team’s availability.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH) and severe alcohol-associated hepatitis (sAH). For more information, please visit www.interceptpharma.com or connect with the Company on Twitter and LinkedIn.
Contact
For more information about Intercept, please contact:
Investor inquiries: investors@interceptpharma.com
Media inquiries: media@interceptpharma.com
The Role of Physiotherapy in Athletic Performance DUBAI, UAE / ACCESSWIRE / December 26, 2024…
CHICAGO, IL / ACCESSWIRE / December 26, 2024 / Cosmos Health Inc. ("Cosmos Health" or…
The CDC estimates that each year, about 385,000 healthcare workers in the United States suffer…
Research highlights how nutrition tracking drives success for weight loss and health goals NEW YORK,…
Coeptis Aims to Bring AI Innovation in Biotechnology and Technology WEXFORD, Pa., Dec. 26, 2024…
Slovenia, Croatia, Turkey, and Greece Drive EHR Adoption in the Balkans, Setting New Standards in…